American Century Companies Inc. Purchases 54,684 Shares of DexCom Inc. (DXCM)
American Century Companies Inc. boosted its position in DexCom Inc. (NASDAQ:DXCM) by 7.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 806,639 shares of the medical device company’s stock after buying an additional 54,684 shares during the period. American Century Companies Inc. owned about 0.97% of DexCom worth $63,991,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in DXCM. Diversified Trust Co purchased a new stake in DexCom during the second quarter worth $1,070,000. Bank of Montreal Can bought a new stake in DexCom during the second quarter worth approximately $134,000. Parametrica Management Ltd bought a new stake in DexCom during the second quarter worth approximately $254,000. CIBC World Markets Inc. bought a new stake in DexCom during the second quarter worth approximately $1,797,000. Finally, Westwood Management Corp IL increased its stake in DexCom by 108.3% in the second quarter. Westwood Management Corp IL now owns 25,000 shares of the medical device company’s stock worth $1,983,000 after buying an additional 13,000 shares in the last quarter. Institutional investors own 99.37% of the company’s stock.
DexCom Inc. (NASDAQ:DXCM) traded down 3.59% on Tuesday, hitting $81.93. The stock had a trading volume of 1,879,239 shares. The company has a 50-day moving average price of $91.52 and a 200-day moving average price of $77.66. DexCom Inc. has a 52 week low of $47.92 and a 52 week high of $96.38. The stock’s market capitalization is $6.87 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The business had revenue of $137.30 million for the quarter, compared to analysts’ expectations of $132.48 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. The business’s quarterly revenue was up 47.3% on a year-over-year basis. Equities research analysts anticipate that DexCom Inc. will post ($0.57) earnings per share for the current fiscal year.
A number of research firms recently commented on DXCM. B. Riley began coverage on DexCom in a report on Monday, September 26th. They issued a “neutral” rating and a $97.00 price objective for the company. Zacks Investment Research downgraded DexCom from a “hold” rating to a “strong sell” rating in a report on Tuesday. Jefferies Group reiterated a “buy” rating and issued a $98.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $100.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $100.00 price objective (up previously from $93.00) on shares of DexCom in a report on Thursday, August 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $95.08.
In other news, insider Jorge A. Valdes sold 32,000 shares of the company’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $79.36, for a total transaction of $2,539,520.00. Following the completion of the transaction, the insider now directly owns 123,667 shares of the company’s stock, valued at $9,814,213.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Terrance H. Gregg sold 35,000 shares of the company’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $79.81, for a total transaction of $2,793,350.00. The disclosure for this sale can be found here. Company insiders own 2.80% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.